FY2024 Earnings Forecast for AURA Issued By Lifesci Capital

Aura Biosciences, Inc. (NASDAQ:AURA) – Analysts at Lifesci Capital issued their FY2024 EPS estimates for Aura Biosciences in a report issued on Tuesday, January 21st. Lifesci Capital analyst O. Mccammon forecasts that the company will post earnings per share of ($1.65) for the year. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.67) per share. Lifesci Capital also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.42) EPS and FY2025 earnings at ($2.52) EPS.

Several other research analysts have also commented on AURA. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. Scotiabank increased their price target on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Finally, BTIG Research boosted their price target on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Aura Biosciences currently has a consensus rating of “Buy” and an average price target of $23.00.

Aura Biosciences Stock Performance

Shares of Aura Biosciences stock opened at $8.10 on Friday. The company has a market capitalization of $404.60 million, a PE ratio of -4.68 and a beta of 0.30. The company has a 50-day simple moving average of $8.45 and a two-hundred day simple moving average of $8.91. Aura Biosciences has a one year low of $6.63 and a one year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Rhumbline Advisers increased its stake in shares of Aura Biosciences by 39.6% in the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after purchasing an additional 18,011 shares in the last quarter. American Century Companies Inc. purchased a new stake in shares of Aura Biosciences in the second quarter valued at approximately $119,000. Dimensional Fund Advisors LP raised its stake in shares of Aura Biosciences by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after buying an additional 41,711 shares during the period. Renaissance Technologies LLC lifted its position in shares of Aura Biosciences by 26.3% during the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after buying an additional 15,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after acquiring an additional 8,194 shares during the period. Institutional investors and hedge funds own 96.75% of the company’s stock.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the transaction, the insider now directly owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Los Pinos Elisabet De sold 9,200 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00. Following the sale, the insider now directly owns 320,647 shares in the company, valued at $3,443,748.78. The trade was a 2.79 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,531 shares of company stock worth $345,454. Company insiders own 5.40% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.